Stockscreener 앱 받기
8.64
2.37%
-0.21
시간 외 거래:
8.64
전일 마감가:
$8.85
열려 있는:
$9.23
하루 거래량:
91,172
Relative Volume:
0.61
시가총액:
$470.04M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-27.03%
1개월 성능:
-28.18%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$8.33
$9.9848
1주일 범위
$8.225
$12.05
52주 변동 폭
$8.225
$13.50
Alumis Inc Stock (ALMS) Company Profile
명칭
Alumis Inc
전화
650-231-6625
주소
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
ALMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ALMS | 8.64 | 470.04M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Alumis Inc 주식(ALMS)의 최신 뉴스
HC Wainwright Has Positive Outlook of Alumis FY2024 Earnings - MarketBeat
FY2024 EPS Estimates for Alumis Reduced by Leerink Partnrs - MarketBeat
Alumis Inc. Reports Q3 2024 Financial Results and Advances Clinical Programs - TipRanks
Alumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 - The Manila Times
Alumis' ESK-001 Shows Promise in Lupus Treatment, New Clinical Data Revealed at ACR 2024 | ALMS Stock News - StockTitan
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
Towerview LLC Buys 70,000 Shares of Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis (NASDAQ:ALMS) Price Target Lowered to $26.00 at HC Wainwright - MarketBeat
Alumis (NASDAQ:ALMS) Given Overweight Rating at Cantor Fitzgerald - MarketBeat
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements - The Manila Times
Alumis Reports 93% Success in Psoriasis Trial, Q3 Loss Widens to $93.1M | ALMS Stock News - StockTitan
U.S. Energy (NASDAQ:USEG) Earns Sell Rating from Analysts at StockNews.com - Defense World
Chase (NYSE:CCF) Coverage Initiated by Analysts at StockNews.com - Defense World
Analysts Set Alumis Inc. (NASDAQ:ALMS) Price Target at $27.50 - MarketBeat
Eventbrite, Inc. (NYSE:EB) Receives Average Rating of “Hold” from Brokerages - Defense World
Alumis readies $300 million IPO ahead of Phase 3 trial for plaque psoriasis drug - MSN
Uveitis Clinical Trials 2024: FDA Approvals, Medication, - openPR
How to Take Advantage of moves in (ALMS) - Stock Traders Daily
New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD - Quantisnow
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - StockTitan
Net Present Value Model: Alumis Inc’s ESK-001 - GlobalData
Alumis (NASDAQ:ALMS) Rating Increased to Strong-Buy at Baird R W - MarketBeat
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Robert W. Baird Begins Coverage on Alumis (NASDAQ:ALMS) - MarketBeat
Baird starts Alumis coverage with Outperform, $25 target - Investing.com India
Baird starts Alumis coverage with Outperform, $25 target By Investing.com - Investing.com South Africa
When (ALMS) Moves Investors should Listen - Stock Traders Daily
Blue Trust Inc. Purchases 307 Shares of Watsco, Inc. (NYSE:WSO) - Defense World
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - MSN
Alumis (NASDAQ:ALMS) Stock Price Down 4.5%Time to Sell? - MarketBeat
Alumis (NASDAQ:ALMS) Trading 3.1% HigherWhat's Next? - MarketBeat
HC Wainwright Predicts Alumis' Q3 Earnings (NASDAQ:ALMS) - MarketBeat
Analysts Set Curbline Properties (NYSE:CURB) PT at $24.19 - Defense World
Ambev (NYSE:ABEV) Now Covered by StockNews.com - Defense World
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside - AOL
Alumis (NASDAQ:ALMS) Shares Gap UpHere's Why - MarketBeat
H.C. Wainwright sets Buy rating on Alumis stock, cites TYK2 inhibitor - Investing.com
H.C. Wainwright sets Buy rating on Alumis stock By Investing.com - Investing.com UK
Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
(ALMS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Shifts in the Psoriasis Market Suggest Strong Potential for Emerging Oral Therapies - GlobeNewswire Inc.
Alumis (NASDAQ:ALMS) Stock Price Down 2.6%What's Next? - MarketBeat
Alumis (NASDAQ:ALMS) Shares Up 6.9%What's Next? - MarketBeat
Millennium Management LLC Takes Position in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Squarepoint Ops LLC Has $240,000 Stock Holdings in Forge Global Holdings, Inc. (NYSE:FRGE) - Defense World
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' - Benzinga
Cramer's Lightning Round: 'I like Target right here' - CNBC
Uveitis Market Growth to Accelerate in Forecast Period - openPR
Alumis (NASDAQ:ALMS) Trading Up 3.8%Time to Buy? - MarketBeat
(ALMS) Technical Pivots with Risk Controls - Stock Traders Daily
Alumis: Could This Broken Immunology IPO Become The Next Amgen? (ALMS) - Seeking Alpha
Alumis Inc (ALMS) 재무 분석
Alumis Inc (ALMS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):